Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T17:06:27.917Z.
Calculation as of: 2026-10-06T17:06:27.917Z.
Quote observation: 2026-10-06T16:58:21.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4cebeea1a9b4d788b134268ad244658713bcf5e38577c227b803d15950d20ec6
PE RATIO
N/A
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares
Market Cap
$5.70M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR) | $5.70M | N/A | N/A | N/A | N/A |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.61M | N/A | N/A | N/A | N/A |
| enVVeno Medical Corporation (NVNO)vs › | $5.77M | N/A | N/A | N/A | N/A |
| Sonoma Pharmaceuticals, Inc. (SNOA)vs › | $5.79M | N/A | 5.41 | 8.45 | 9.86 |
| Lucyd, Inc (LUCY)vs › | $5.82M | N/A | N/A | N/A | N/A |
| Scienture Holdings, Inc. (SCNX)vs › | $5.91M | N/A | N/A | N/A | N/A |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $5.98M | N/A | N/A | N/A | N/A |
| Pulmatrix, Inc. (PULM)vs › | $5.41M | N/A | N/A | N/A | N/A |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.31M | N/A | N/A | N/A | N/A |
| Soligenix, Inc. (SNGX)vs › | $5.38M | N/A | 56.51 | 56.51 | 56.51 |
Trailing P/E
N/A
Forward P/E
N/A
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
